Search Results

Glaucoma Drugs in the Pipeline

Physicians share which coming therapies they are most eager to use in their practices.

Malik Y. Kahook, MD; Paul L. Kaufman, MD; Robert J. Noecker, MD, MBA; and Nathan M. Radcliffe, MD

Glaucoma Drugs in the Pipeline

Physicians share which coming therapies they are most eager to use in their practices.

Malik Y. Kahook, MD; Paul L. Kaufman, MD; Robert J. Noecker, MD, MBA; and Nathan M. Radcliffe, MD

In Memoriam: 5 Questions With David L. Epstein, MD

Dr. Epstein stresses the need for MD clinician scientists and an interdisciplinary approach in glaucoma research.

Research Results

Highlights of the AGS Annual Meeting

The latest research findings from a joint meeting of the American Glaucoma Society and the Australian and New Zealand Glaucoma Interest Group held March 5 to 8, 2009, in San Diego.

Geoffrey T. Emerick, MD

An Overview of Statins

How this class of drugs became of interest in glaucoma, and why research continues.

David L. Epstein, MD

Koniocellular Pathway Damage in Glaucoma

Ocular hypertension affects the blue/yellow neurons.

Yeni H. Yücel, MD, PhD; Robert N. Weinreb, MD; Paul L. Kaufman, MD; and Neeru Gupta, MD, PhD

Koniocellular Pathway Damage in Glaucoma

Ocular hypertension affects the blue/yellow neurons.

Yeni H. Yücel, MD, PhD; Robert N. Weinreb, MD; Paul L. Kaufman, MD; and Neeru Gupta, MD, PhD

5 Questions With David L. Epstein, MD

David L. Epstein, MD

5 Questions With Paul L. Kaufman, MD

Paul L. Kaufman, MD

5 Questions With Robert Ritch, MD

Robert Ritch, MD